Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Centre Hospitalier Universitaire De Montpellier has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners across 2 distinct art units.
JACKSON III, WALTER is the busiest examiner with 1 pending matter. Counsel can coordinate scientific terminology across the portfolio while addressing each examiner’s grounds and the separate application disclosures.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18832633 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING TEAR FILM COMPOSITION TO TREAT CORNEAL DEFECTS | JACKSON III, WALTER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267957 | PRE-TREATMENT OF MSC WITH PPARB/DELTA AGONIST FOR TREATMENT OF ISCHEMIA-REPERFUSION INJURY | KIM, TAEYOON | 13d |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18832633 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING TEAR FILM COMPOSITION TO TREAT CORNEAL DEFECTS | JACKSON III, WALTER | 1638 | §102§103 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18267957 | PRE-TREATMENT OF MSC WITH PPARB/DELTA AGONIST FOR TREATMENT OF ISCHEMIA-REPERFUSION INJURY | KIM, TAEYOON | 1631 | §103 | Final Rejection | 13d | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre Hospitalier Universitaire De Montpellier has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Walter Jackson III has the most, with 1 of Centre Hospitalier Universitaire De Montpellier's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
